We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PSNL:NASDAQPersonalis, Inc. Analysis

Data as of 2026-06-21 - not real-time

$10.54

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Personalis, Inc. trades at $10.54, comfortably above its 20‑day ($10.09), 50‑day ($7.76) and 200‑day ($8.05) simple moving averages, indicating short‑term price strength, yet the MACD histogram is negative and the MACD line sits below its signal, flagging bearish momentum. The RSI of 62 reinforces moderate upside pressure without being overbought, while decreasing volume and a 30‑day volatility of ~90% signal a fragile rally. The stock’s beta (>3) and a max drawdown of –55% underscore extreme sensitivity to market swings, and the current price sits midway between a clear support level at $7.70 and resistance near $12.53. On the fundamentals side, the company posts negative gross (13.7%) and operating margins (‑2.1%), a trailing EPS of –$1.02, and a forward PE of –11.8, reflecting ongoing loss generation. Despite the losses, a strong cash pile of $233 M versus $38.8 M of debt provides a solid liquidity cushion, though free cash flow remains deeply negative. The diagnostics sector faces high regulatory scrutiny, and the “Extreme Greed” market sentiment (fear‑greed index 91) may be inflating the price beyond intrinsic value. Overall, the blend of bullish technical positioning, deteriorating cash‑flow fundamentals, and heightened volatility suggests caution pending a clear earnings or partnership catalyst.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD histogram and signal divergence
  • Decreasing volume trend amid high volatility
  • Large max drawdown indicating downside vulnerability

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Substantial cash reserves offsetting debt load
  • Potential upside from strategic collaborations in oncology
  • Neutral trend direction despite mixed technical signals

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Long‑term growth prospects in cancer genomics and liquid biopsy
  • Strategic partnership with Tempus AI expanding market reach
  • Industry tailwinds for precision‑medicine diagnostics

Key Metrics & Analysis

Financial Health

Revenue Growth-24.90%
Profit Margin-148.11%
P/E Ratio-11.8
ROE-41.35%
ROA-21.41%
Debt/Equity15.22
P/B Ratio4.3
Op. Cash Flow$-79463000
Free Cash Flow$-42353248
Industry P/E24.1

Technical Analysis

TrendNeutral
RSI62.1
Support$7.70
Resistance$12.53
MA 20$10.09
MA 50$7.76
MA 200$8.05
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Target Price$10.86
Upside/Downside3.01%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta3.04
Volatility90.63%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.